International Biotechnology (LON:IBT) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

International Biotechnology (LON:IBT)’s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 684.42 ($8.33) and traded as high as GBX 703.25 ($8.56). International Biotechnology shares last traded at GBX 702 ($8.54), with a volume of 145,383 shares trading hands.

International Biotechnology Price Performance

The company has a debt-to-equity ratio of 9.66, a current ratio of 0.46 and a quick ratio of 0.32. The stock’s 50 day moving average price is GBX 694.71 and its two-hundred day moving average price is GBX 684.87. The firm has a market capitalization of £256.50 million, a price-to-earnings ratio of 1,445.83 and a beta of 0.21.

International Biotechnology Increases Dividend

The company also recently announced a dividend, which will be paid on Friday, January 24th. Shareholders of record on Thursday, December 19th will be given a dividend of GBX 15.56 ($0.19) per share. This is a positive change from International Biotechnology’s previous dividend of $14.50. The ex-dividend date of this dividend is Thursday, December 19th. This represents a yield of 2.21%. International Biotechnology’s payout ratio is currently 6,041.67%.

Insider Buying and Selling at International Biotechnology

In other International Biotechnology news, insider Katherine Cornish-Bowden purchased 1,500 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were bought at an average cost of GBX 713 ($8.68) per share, with a total value of £10,695 ($13,012.53). Corporate insiders own 4.18% of the company’s stock.

About International Biotechnology

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.